Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles
Betty M. Tijms(Amsterdam Neuroscience), Pieter Jelle Visser(Karolinska Institutet), Luigi Lorenzini(Amsterdam Neuroscience), Olav Mjaavatten(University of Bergen), Wiesje M. van der Flier(Amsterdam Neuroscience), Frode S. Berven(University of Bergen), Julie Goossens(ADx NeuroSciences), Lianne M. Reus(Amsterdam Neuroscience), Henne Holstege(Allen Institute for Brain Science), Anouk den Braber(Max Planck Institute for Psycholinguistics), Sven J. van der Lee(Amsterdam Neuroscience), Vikram Venkatraghavan, Frederik Barkhof(Netherlands Institute for Neuroscience), Charlotte E. Teunissen(Amsterdam Neuroscience), Eugeen Vanmechelen(ADx NeuroSciences), Kirsten E. J. Wesenhagen(Amsterdam Neuroscience), Jori Tomassen(MACOM (United States)), Yolande A.L. Pijnenburg(Amsterdam Neuroscience), Eleonora M. Vromen(Amsterdam Neuroscience), Niccoló Tesi(Amsterdam UMC Location University of Amsterdam), Lisa Vermunt(Amsterdam Neuroscience)
Cited by 195
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k